Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerome B Zeldis

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Drug Discovery Today|February 19, 2005
Thalidomide as a novel therapeutic agent: new uses for an old productSteve K Teo, David I Stirling, Jerome B Zeldis
Annals of the New York Academy of Sciences|March 26, 2011
A review of the history, properties, and use of the immunomodulatory compound lenalidomideJerome B Zeldis, Robert Knight, Mohamad Hussein, et al.
Expert Opinion on Pharmacotherapy|March 10, 2010
Lenalidomide in multiple myeloma: current role and future directionsJerome B Zeldis, Robert D Knight, Christian Jacques, et al.
Seminars in Oncology|April 30, 2003
Potential new therapeutics for Waldenstrom's macroglobulinemiaJerome B Zeldis, Peter H Schafer, Brydon L Bennett, et al.
Drug Safety|January 12, 2017
Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge RetentionNancy A Brandenburg, Robert Bwire, John Freeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2006
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoringLinda Mileshkin, Richard Stark, Bruce Day, et al.
British Journal of Haematology|March 8, 2008
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulationMatthew J Streetly, Kylie Gyertson, Yvonne Daniel, et al.
Drug Safety|August 19, 2008
RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomideCarmen P Castaneda, Jerome B Zeldis, John Freeman, et al.
Frontiers in Immunology|July 6, 2016
Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosisSelvakumar Subbian, Mi-Sun Koo, Liana Tsenova, et al.
Journal of Clinical Pharmacology|October 24, 2007
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisNianhang Chen, Henry Lau, Linghui Kong, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Drug Discovery Today|February 19, 2005
Thalidomide as a novel therapeutic agent: new uses for an old productSteve K Teo, David I Stirling, Jerome B Zeldis
Annals of the New York Academy of Sciences|March 26, 2011
A review of the history, properties, and use of the immunomodulatory compound lenalidomideJerome B Zeldis, Robert Knight, Mohamad Hussein, et al.
Expert Opinion on Pharmacotherapy|March 10, 2010
Lenalidomide in multiple myeloma: current role and future directionsJerome B Zeldis, Robert D Knight, Christian Jacques, et al.
Seminars in Oncology|April 30, 2003
Potential new therapeutics for Waldenstrom's macroglobulinemiaJerome B Zeldis, Peter H Schafer, Brydon L Bennett, et al.
Drug Safety|January 12, 2017
Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge RetentionNancy A Brandenburg, Robert Bwire, John Freeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2006
Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoringLinda Mileshkin, Richard Stark, Bruce Day, et al.
British Journal of Haematology|March 8, 2008
Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulationMatthew J Streetly, Kylie Gyertson, Yvonne Daniel, et al.
Drug Safety|August 19, 2008
RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomideCarmen P Castaneda, Jerome B Zeldis, John Freeman, et al.
Frontiers in Immunology|July 6, 2016
Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosisSelvakumar Subbian, Mi-Sun Koo, Liana Tsenova, et al.
Journal of Clinical Pharmacology|October 24, 2007
Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysisNianhang Chen, Henry Lau, Linghui Kong, et al.
Pageof 5